
Quarterly report 2025-Q3
added 11-05-2025
OraSure Technologies Long-Term Debt 2011-2026 | OSUR
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt OraSure Technologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113 K | 226 K | 503 K | 1.95 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.95 M | 113 K | 698 K |
Quarterly Long-Term Debt OraSure Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117 K | 133 K | 102 K | 113 K | 124 K | 267 K | 204 K | 226 K | - | 436 K | 472 K | 503 K | 935 K | 1.44 M | 1.21 M | 1.95 M | 2.83 M | 1.57 M | 762 K | 895 K | 895 K | 895 K | 895 K | 1.37 M | 1.37 M | 1.37 M | 1.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.83 M | 102 K | 864 K |
Long-Term Debt of other stocks in the Medical instruments industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
13.2 B | $ 20.66 | 1.27 % | $ 10.5 B | ||
|
Becton, Dickinson and Company
BDX
|
17.6 B | $ 205.09 | 1.16 % | $ 59 B | ||
|
Ekso Bionics Holdings
EKSO
|
452 K | $ 8.15 | -7.6 % | $ 164 M | ||
|
Luminex Corporation
LMNX
|
203 M | - | - | $ 1.75 B | ||
|
Harvard Bioscience
HBIO
|
30.7 M | $ 0.66 | -1.92 % | $ 28 M | ||
|
iRhythm Technologies
IRTC
|
74.6 M | $ 188.16 | 0.41 % | $ 5.87 B | ||
|
Antares Pharma, Inc.
ATRS
|
24.7 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
1.05 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
70.6 M | - | - | $ 282 M | ||
|
Masimo Corporation
MASI
|
728 M | $ 138.18 | 0.8 % | $ 7.36 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
1.66 B | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
288 M | - | -0.02 % | $ 16.3 B | ||
|
Haemonetics Corporation
HAE
|
921 M | $ 84.98 | 2.36 % | $ 4.28 B | ||
|
Alcon
ALC
|
3.95 B | $ 80.67 | -0.38 % | $ 40.4 B | ||
|
Predictive Oncology
POAI
|
1.56 M | $ 6.85 | 3.24 % | $ 37.4 M | ||
|
AtriCure
ATRC
|
61.9 M | $ 42.59 | 1.96 % | $ 2 B | ||
|
electroCore
ECOR
|
537 K | $ 5.15 | 6.19 % | $ 28.4 K | ||
|
ICU Medical
ICUI
|
1.53 B | $ 152.88 | 1.7 % | $ 3.73 B | ||
|
AngioDynamics
ANGO
|
5.8 M | $ 10.02 | -8.29 % | $ 409 M | ||
|
The Cooper Companies
COO
|
2.46 B | $ 83.38 | -0.63 % | $ 16.6 B | ||
|
Isoray
ISR
|
1.68 M | - | 0.03 % | $ 108 M | ||
|
STERIS plc
STE
|
1.92 B | $ 260.64 | 0.52 % | $ 25.7 B | ||
|
Glaukos Corporation
GKOS
|
70.5 M | $ 114.49 | 0.43 % | $ 5.55 B | ||
|
InfuSystem Holdings
INFU
|
33.2 M | $ 8.9 | -0.11 % | $ 184 M | ||
|
Repro Med Systems
KRMD
|
317 K | $ 5.79 | 3.02 % | $ 264 M | ||
|
LeMaitre Vascular
LMAT
|
168 M | $ 85.05 | 1.55 % | $ 1.91 B | ||
|
Intuitive Surgical
ISRG
|
112 M | $ 586.15 | -1.03 % | $ 208 B | ||
|
Merit Medical Systems
MMSI
|
730 M | $ 93.33 | 1.83 % | $ 5.43 B | ||
|
Utah Medical Products
UTMD
|
396 K | $ 58.5 | 1.39 % | $ 212 M | ||
|
Nephros
NEPH
|
1.39 M | $ 5.07 | -1.74 % | $ 52.7 M | ||
|
Microbot Medical
MBOT
|
40 K | $ 2.19 | 3.55 % | $ 22.3 M | ||
|
Milestone Scientific
MLSS
|
54.7 K | $ 0.29 | 2.24 % | $ 23.1 M | ||
|
NeuroMetrix
NURO
|
92.5 K | - | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
1.28 B | $ 23.52 | 2.53 % | $ 4.05 B | ||
|
Pro-Dex
PDEX
|
15.4 M | $ 41.83 | 4.47 % | $ 138 M | ||
|
Pulse Biosciences
PLSE
|
8.09 M | $ 14.71 | -3.26 % | $ 707 M | ||
|
Repligen Corporation
RGEN
|
510 M | $ 165.12 | -2.32 % | $ 9.2 M | ||
|
ResMed
RMD
|
765 M | $ 250.85 | 1.07 % | $ 36.6 B | ||
|
BioLife Solutions
BLFS
|
5 M | $ 24.91 | -1.97 % | $ 1.15 B | ||
|
Stereotaxis
STXS
|
5.06 M | $ 2.57 | -1.35 % | $ 207 M | ||
|
Retractable Technologies
RVP
|
900 K | $ 0.76 | -0.53 % | $ 22.8 M | ||
|
STAAR Surgical Company
STAA
|
34.8 M | $ 22.43 | 1.08 % | $ 1.1 B | ||
|
Teleflex Incorporated
TFX
|
1.56 B | $ 110.0 | -13.07 % | $ 5.15 B | ||
|
West Pharmaceutical Services
WST
|
203 M | $ 274.0 | -1.62 % | $ 20 B | ||
|
DENTSPLY SIRONA
XRAY
|
1.59 B | $ 12.53 | 1.25 % | $ 2.55 B |